We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Urine Trumps Blood For Zika Testing

By LabMedica International staff writers
Posted on 08 Jun 2016
Limited data suggest Zika virus is excreted in multiple body fluids, including urine and saliva and that urine and saliva might be more appropriate specimens than blood samples for evaluating Zika virus disease.

The interim diagnostic testing guidance for the Zika virus recommends real-time reverse transcription-polymerase chain reaction (rRT-PCR) testing for urine specimens obtained two weeks after the illness starts. More...
The Zika virus ribonucleic acid (RNA) is almost undetectable in blood samples after the first week of illness.

Scientists from the Centers for Disease Control and Prevention (CDC, Atlanta GA, USA) and their colleagues collected multiple specimen types from persons with suspected Zika virus disease. Urine specimens were collected from 70 patients with suspected Zika virus disease from zero to 20 days after symptom onset. In 66 cases, persons had urine and serum specimens collected on the same day. The majority of these persons were female (64%), white (77%), and Hispanic (71%), with a median age of 46 years, age range 23 to76 years.

Zika virus rRT-PCR was performed at the Bureau of Public Health Laboratories (BPHL, Tampa, FL, USA) using a laboratory-developed test based on a previously published protocol using two RT-PCR targets. The teams found urine samples were the best at flagging Zika, with 93% of specimens collected within 20 days of symptoms first appearing showing positive results. Urine specimens also displayed positive results 82% of the time when samples were collected more than five days after symptoms cropped up. Urine samples were positive 95% of the time when the specimens were obtained the same day or within five days of illness onset as compared to 56% for blood samples.

The authors concluded that the results of testing conducted suggest that urine might be the preferred specimen type to identify acute Zika virus disease. Rates of detection from urine were higher than from serum, even during the first few days after symptom onset and continuing after day five, when no serum specimens tested in this evaluation had detectable RNA. Among pregnant women, this ability to confirm Zika virus is important because close monitoring during pregnancy is recommended for women with confirmed Zika virus disease.

The ease of collection of urine specimens is an additional advantage. This report also demonstrated that saliva specimens (another specimen that is easily obtained) can also yield a higher rate of RNA detection than serum even during the first five days; the detection rate in saliva also approaches the detection rate in urine. However, no cases were identified through saliva testing alone. The study was published on May 13, 2016, in the journal Morbidity and Mortality Report.

Related Links:
Centers for Disease Control and Prevention
Bureau of Public Health Laboratories


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
PSA Test
Humasis PSA Card
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: Schematic diagram of multimodal single-cell MSI using tapping-mode scanning probe electrospray ionization (Photo courtesy of Yoichi Otsuka)

New Technology Improves Understanding of Complex Biological Samples

Tissues are composed of a complex mixture of various cell types, which complicates our understanding of their biological roles and the study of diseases. Now, a multi-institutional team of researchers... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.